PainReform (PRFX) has released an update.
Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
PainReform, a clinical-stage pharmaceutical company, received a notification from Nasdaq for not meeting the minimum stockholders’ equity requirement. Despite this, the company’s shares will continue to trade on Nasdaq, and they have until December 19, 2024, to submit a compliance plan. PainReform is focused on developing PRF-110, a product aiming to provide extended postoperative pain relief.
For further insights into PRFX stock, check out TipRanks’ Stock Analysis page.
